Tech Company Financing Transactions
Xanodyne Pharmaceuticals Funding Round
On 6/1/2004, Xanodyne Pharmaceuticals raised $20 million in Series C funding from EW Healthcare Partners, Blue Chip Venture Company and HealthCare Ventures.
Transaction Overview
Company Name
Announced On
6/1/2004
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds of the financing will be used to expand its national field sales team and fund its development programs for Misopess (for cervical ripening) and XP012B (for menorrhagia), both of which will enter Phase III later this year.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
One Riverfront Place
Newport, KY 41071
USA
Newport, KY 41071
USA
Phone
Website
Email Address
Overview
Xanodyne is a specialty pharmaceutical company with commercial and development capabilities for providing better patient care in women's health and pain management.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Natasha Giordano
Chief Financial Officer
Rita O'Connor
Chief Operating Officer
Fabrice Egros
VP - Regulatory Affairs
Thomas Jennings
Browse more venture capital transactions:
Prev: 6/1/2004: Virtusa venture capital transaction
Next: 6/2/2004: NorthStar Systems International venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs